NVIDIA and the UW Medicine Institute for Protein Design debuted RFD4-Proteina, an open model that combines programmable protein design with search capabilities so scientists and agents can refine designs using constraints and scoring objectives. In reported testing, it achieved higher computational design success rates and throughput than baselines across 4 benchmark suites. Siemens Healthineers is working with NVIDIA on next-generation adaptive radiotherapy using agentic co-planning, patient-specific simulation and robotic control. Automata, Benchling, Danaher and others are using the BioNeMo platform to build scientific agents that link drug design, autonomous labs and biological discovery. Projections show about 35 million people worldwide will be diagnosed with cancer each year by 2050.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Nvidiaartificial intelligencehealthcarepharmaceuticals
Open a keyword to see other news on the same topic.
Related tickers and likely impact
NVDA
• NeutralNvidia
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Semiconductors |
| Market cap | $5.2T |
| Close on 10/20/2026 | 216.48 |
| Change that session | -0.28% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Nvidia-Backed AI Biotech Iambic Up 16% After $150 Million IPO
Iambic Therapeutics, a San Diego-based cancer drugmaker and technology firm that uses AI to discover new treatments, raised $150 million in its US IPO. Shares rose 16% in their trading debut, to $18.50 versus the $16 IPO price, giving the company a market value of $877 million. The proceeds will advance three early-stage cancer drug candidates; Nvidia is a shareholder, and ARK Investment Management and Stanley Druckenmiller's Duquesne Family Office had expressed interest in buying up to $60 million of shares. For the six months ended June 30, 2026, Iambic posted a net loss of $50.1 million on $12.8 million in revenue, versus a $33.2 million loss on $3.9 million revenue a year earlier. After the offering, Catalio's stake is expected to fall from 11% to 8.9%, and Nexus Venture Partners' from 8.5% to 6.8%.
- Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026
Rapid Micro Biosystems (Nasdaq: RPID) said it will sponsor the PDA Pharmaceutical Microbiology Conference 2026 in Washington, D.C., October 26-28, and invites visitors to Booth 101. Its Growth Direct platform will be featured in a presentation by Sophia Pfeiffer of Boehringer Ingelheim on Monday, October 26 at 1:10 p.m. ET, covering early detection of mold contamination using computer vision and AI. The company describes Growth Direct as an industry-leading, fully automated, non-destructive, growth-based platform for microbial quality control testing.
- What Danaher Stock's AI Lab Push Means For Shareholders
Danaher has announced a collaboration with NVIDIA combining its instruments, automation and software with NVIDIA's AI platforms, along with an AI-powered autonomous lab at Abcam for faster custom antibody development. The article links this push to future demand for more automated, data-rich research, but says it does not fundamentally change near-term risk-reward given China trade frictions and volume-based procurement. Analyst models already assume 8.1% annual revenue growth over three years and margin expansion from 15.9% to 19.3%, so the AI initiatives sit within existing expectations. Consensus sees profit rising from US$4.0b today to about US$6.1b by 2029, with the central target of US$236.32 against a US$214.06 share price. The mid case implies a P/E of about 34.1x on 2029 earnings, versus 37.7x today.
- Danaher (DHR) Teams Up To Bring AI Into Scientific Research Workflows
Danaher (NYSE:DHR) announced a collaboration with NVIDIA to apply AI and accelerated computing across its scientific tools and workflows. The focus is embedding NVIDIA AI platforms into research instruments to support automation and data-rich experiments. The move extends Danaher's AI-enabled science push after its autonomous lab initiative at Abcam, and its instruments are used in universities, biopharma labs and industrial settings.
- Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
- Changes to This $100 Billion Federal Drug Program Could Make Banks the Hidden Beneficiaries
A proposed overhaul of the $100 billion federal 340B drug-discount program would shift some discounts to rebates starting January 1, 2027, so hospitals must pay upfront and wait for reimbursement. In an illustrative example, an extra $10 million balance at 6% annual interest would cost about $50,000 per month, which could increase demand for credit lines from banks that already serve hospitals. The American Hospital Association estimates administrative costs could exceed $1 billion per year, compared with HRSA's $537 million estimate for submitting claims. The article notes the incremental lending demand is unquantified, and the program faces a lawsuit filed on October 9 after an earlier rebate pilot was blocked in December 2025. Banks would benefit only if added interest exceeds funding costs and credit losses.
Related markets
Latest news
- BlackBerry Jumps 6% as Record QNX Backlog Extends Rally, Now Up 149% YTD; Mobileye Drops 4%, Aptiv Dips
BlackBerry stock rose 6% to $9.45 in afternoon trading after the company said its QNX unit’s royalty backlog exceeded $1.2 billion, a record, and the stock is up 149% year to date. Management credited growing adoption of the QNX Software Development Platform and the first deal for Alloy Kore, which it called the largest design win in QNX’s history, along with wins in robotics, industrial automation and medical devices. Over the same period, Mobileye fell 4% to $7 and Aptiv slipped 0.6% to $44.79, while the Global X Autonomous & Electric Vehicles ETF rose 0.1%. The article explains that QNX earns licensing royalties as vehicle programs enter production, whereas Mobileye and Aptiv carry heavier hardware content. The key question now is whether the backlog converts into royalty revenue on schedule, which depends on when automakers move programs into production.
- On October 22, how much interest would 100 million VND earn after 24 months at 7 banks?
Based on listed rates for a 24-month term with interest paid at maturity, VPBank offers the highest counter rate at 6.9% per year (VND 13.8 million in interest), followed by MB at 6.5% (VND 13 million) and Sacombank at 6.2% (VND 12.4 million). Techcombank has the lowest counter rate in the compared group at 4.85% per year, or VND 9.7 million. For online deposits, Sacombank leads at 7.3% per year (VND 14.6 million), followed by VPBank at 7.1% (VND 14.2 million), while HDBank pays 5% (VND 10 million) and Techcombank 5.35% (VND 10.7 million); ACB has no 24-month online rate data. The rates are compiled from bank rate schedules, apply to specific products and deposit amounts, and may change over time or by agreement with depositors.
- TeraWulf Jumps 8% as CEO Says Power Demand Remains ‘Extremely Strong’; Applied Digital Surges 9%, IREN Climbs 6%
TeraWulf shares rose 8% to $12.95 in afternoon trading after CEO Paul B. Prager wrote on X that demand for power “remains extremely strong,” that the company’s site is “energized” to meet it, and that shareholders would not be diluted. He said customers would likely need outside funding but TeraWulf would not take on that financial risk, and that the next data center building at Lake Mariner, leased to Fluidstack, is on track for delivery this quarter. Applied Digital rose 9% to $21.17 and IREN climbed 6% to $28.11, while the CoinShares Bitcoin Mining and Digital Power ETF gained 3% to $32.43 against a 0.6% rise in the SPDR S&P 500 ETF Trust. The article links the rally to power scarcity, including Elon Musk’s comment on the earnings call that the infrastructure to supply and cool electrical equipment is “somewhat of a limiting factor” for superintelligence. The next test for TeraWulf is whether the Lake Mariner building is delivered on schedule this quarter.
- Why Pegasystems Stock Dropped After Earnings
Pegasystems shares slipped 3.6% by 1:30 p.m. ET on Wednesday after the company reported Q3 results well below analyst forecasts. Analysts expected $0.49 per share on $421.8 million in sales, but Pegasystems earned $0.35 per share on a non-GAAP basis with sales below $393.4 million, and GAAP earnings were only $0.08 per share. Sales grew 3% year over year, GAAP profit fell 68%, and annual contract value rose 6%, which CEO Alan Trefler and CFO Ken Stillwell cited as grounds for confidence. The article argues free cash flow matters more to investors: the company generated $490 million last year and is running at about $438 million annualized, and Stillwell projects $700 million or more by 2028. The article calculates that this would imply near-term free cash flow growth north of 25%.
- Salesforce (CRM) vs Oracle (ORCL): Which Is a Better Stock to Buy?
Salesforce closed at $242.45 on October 19 and gained 30.2% over six months, versus 8.7% for the State Street SPDR S&P 500 ETF Trust, while Oracle closed at $129.59 after losing more than a quarter of its value over the same period. The article describes Salesforce’s customer records and workflows as hard to replace, with $14.4 billion of free cash flow in its last fiscal year, but notes slow growth, with revenue up 10.80% last quarter, and a deal announced October 20 to buy Braze for $5.66 billion. Its seat-based pricing could be a risk if AI agents take on work that staff used to do. Oracle grew revenue 29.60% last quarter at a 35.63% operating margin, supported by database support contracts, but its build-out of AI computing capacity carries debt equal to 251.72% of equity and levered free cash flow of negative $45.85 billion over the past year. The article adds that renting computing capacity earns a thinner margin than licensing software.
- Cold Water: Tesla and SpaceX Merger “Won’t Add Much Value” per Gary Black
Gary Black, managing partner of The Future Fund, argues that an all-stock Tesla–SpaceX deal at about $420 per Tesla share, roughly 10% above the current price, would add little value. Tesla trades at 191.6x forward earnings, well above its three-year average of 135.1x and above SpaceX's multiple, so the combined company would likely be valued at SpaceX's lower level. Tesla's normalized EPS fell from $3.12 in fiscal 2023 to $1.66 in fiscal 2025, with analysts expecting $2.17 in fiscal 2027. Musk said special committees at both companies are studying the idea and that he thinks it would be a good idea, but no terms have been agreed.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.